利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.046 秒)

    Converting diploidy to haploidy for genetic diagnosis
    1.
    发明授权
    Converting diploidy to haploidy for genetic diagnosis 失效
    将二倍体转化为单倍体用于遗传诊断

    公开(公告)号：US06399374B1

    公开(公告)日：2002-06-04

    申请号：US09461047

    申请日：1999-12-15

    申请人： Bert Vogelstein ,  Kenneth W. Kinzler ,  Hai Yan ,  Nicholas Papadopoulos

    发明人： Bert Vogelstein ,  Kenneth W. Kinzler ,  Hai Yan ,  Nicholas Papadopoulos

    IPC分类号： C12N512

    CPC分类号： C12N5/166 ,  C12Q1/6886 ,  C12Q2600/156

    摘要： Detection of mutations associated with hereditary diseases is complicated by the diploid nature of human cells. Mutations present in one allele are often masked by the wild-type sequence of the other allele. Individual alleles can be isolated from every chromosome within somatic cell hybrids generated from a single fusion. Nucleic acids from the hybrids can be analyzed for mutations in an unambiguous manner. This approach was used to detect two cancer-causing mutations that had previously defied genetic diagnosis. One of the families studied, Warthin Family G, was the first kindred with a hereditary colon cancer syndrome described in the biomedical literature.

    摘要翻译： 与遗传性疾病相关的突变的检测由于人类细胞的二倍体性质而复杂化。 存在于一个等位基因中的突变通常被其他等位基因的野生型序列掩蔽。 可以从单次融合产生的体细胞杂交体内的每个染色体分离个体等位基因。 来自杂种的核酸可以以明确的方式分析突变。 这种方法被用于检测先前不符合遗传诊断的两种致癌突变。 研究的家庭之一，Warthin Family G，是生物医学文献中描述的第一个遗传性结肠癌综合症患者。

    Fusion polypeptides capable of activating receptors
    5.
    发明授权
    Fusion polypeptides capable of activating receptors 有权
    能够激活受体的融合多肽

    公开(公告)号：US07534604B2

    公开(公告)日：2009-05-19

    申请号：US11035599

    申请日：2005-01-14

    申请人： James P. Fandl ,  Gang Chen ,  Nicholas Papadopoulos ,  Thomas H. Aldrich

    发明人： James P. Fandl ,  Gang Chen ,  Nicholas Papadopoulos ,  Thomas H. Aldrich

    IPC分类号： C12P21/04 ,  C12N5/00 ,  C07H21/04

    CPC分类号： C07K16/2863 ,  C07H21/04 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/75 ,  C07K2319/30

    摘要： A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different ScFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.

    摘要翻译： 包含（A）x-M-（A'）y的融合多肽，其中A和A'是能够结合靶受体的多肽。 本发明的融合多肽形成激活靶受体的多聚体蛋白。 A和A'可以各自为衍生自靶受体（例如相同或不同ScFv片段）的特异性抗体的抗体或片段，和/或能够结合靶蛋白质的配体或配体片段或衍生物，M为 多聚化组分，X和Y独立地为1-10之间的数。

    Therapeutic methods for treating vascular eye disorders with DII4 antagonists
    6.
    发明申请
    Therapeutic methods for treating vascular eye disorders with DII4 antagonists 审中-公开
    用DII4拮抗剂治疗血管性眼病的治疗方法

    公开(公告)号：US20080181893A1

    公开(公告)日：2008-07-31

    申请号：US11890741

    申请日：2007-08-07

    申请人： Ivan B. Lobov ,  Nicholas Papadopoulos ,  Stanley J. Wiegand

    发明人： Ivan B. Lobov ,  Nicholas Papadopoulos ,  Stanley J. Wiegand

    IPC分类号： A61K39/395 ,  A61P27/02

    CPC分类号： C07K16/2863 ,  A61K38/1709 ,  A61K2039/505 ,  C07K2317/76 ,  C07K2319/30

    摘要： A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (Dll4) activity to a subject in need thereof. In one embodiment, the agent is an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor. The method of the invention is useful for treating eye disorders such as ischemic retinopathy, diabetic retinopathy, age related macular degeneration, corneal neovascularization, neovascular glaucoma, or retinopathy of prematurity. The method is also useful or treating ischemic or vascular disorders such as ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension.

    摘要翻译： 一种通过向有需要的受试者施用能够抑制人类δ样配体4（Dll4）活性的试剂来治疗缺血性或血管性疾病的治疗方法。 在一个实施方案中，该试剂是能够抑制Dll4与Notch受体结合的抗Dll4抗体或抗体片段。 本发明的方法可用于治疗眼部疾病如缺血性视网膜病变，糖尿病性视网膜病变，年龄相关性黄斑变性，角膜新生血管形成，新生血管性青光眼或早产儿视网膜病变。 该方法还可用于治疗缺血性或血管性疾病，例如缺血性损伤，脑缺血，心脏缺血，影响肢体和其他器官或组织的缺血状况，动静脉畸形，伤口愈合，器官或组织移植，胎盘功能不全，动脉狭窄和 闭塞，动脉粥样硬化和全身或肺动脉高压。